TOKYO -- Japan will not be able to receive a stable supply of promising coronavirus therapy remdesivir from its U.S. developer to treat all patients in need, Nikkei learned Friday.
Remdesivir's developer, Gilead Sciences, plans to distribute enough doses to cover 140,000 patients worldwide, but Japan will receive only a small portion of the supply.
